Tharimmune to Present at the Microcap Conference 2025
-
Trains collide near Jakarta, killing four, injuring dozens
-
Kompany hails Kane, 'ageing like fine wine' as Bayern face PSG in Champions League
-
UK's King Charles arrives in US to shore up Trump ties
-
Tuareg rebels in control of key Mali town
-
US Supreme Court hears Bayer bid to end Roundup weedkiller suits
-
Separate goals, common enemy for Mali's jihadists and separatists
-
Accused media gala shooter charged with attempted Trump assassination
-
UK's King Charles seeks to shore up Trump ties
-
Tourism plummets in US-blockaded Cuba
-
Taylor Swift files to trademark her voice amid AI clone boom
-
Trains collide outside Jakarta, killing four: officials
-
EU tells Google to open Android to AI rivals
-
Italian Calzona quits as Slovakia coach
-
21 killed in deadliest Colombia bombing in decades
-
Hazlewood, Kumar spark Delhi collapse as Bengaluru romp to victory
-
UN maritime agency rejects Hormuz tolls
-
Human Rights Watch warns of 'exclusion and fear' at World Cup
-
Tuareg rebels in control of key Mali town after offensive
-
Joshua signs deal to face Fury in all-British grudge match
-
Melania Trump slams Kimmel joke likening her to an 'expectant widow'
-
Carney launches $18 billion Canada sovereign wealth fund
-
Modric suffers fractured cheekbone, will go under the knife: AC Milan
-
'Looming' risk of nuclear arms race, UN proliferation meeting hears
-
Suspect due in court over shooting at Trump gala
-
Sabalenka downs Osaka to reach Madrid Open quarter-finals
-
'Nobody is better than us' says Luis Enrique as PSG prepare for Bayern
-
Hridoy, Shamim pull off record home chase for Bangladesh against NZ
-
Thrilling Kvaratskhelia hoping to drive PSG to another Champions League final
-
Swiss canton votes with centuries-old show of hands
-
Mali attacks kill defence minister, deepening security crisis
-
How remarkable Sawe made marathon history in London
-
British Open to be staged at Royal Lytham and St Annes in 2028
-
Mbappe doubt for Clasico after Real Madrid confirm thigh injury
-
Salah will get fitting Liverpool farewell despite injury, says Van Dijk
-
African players in Europe: Injury may end Salah's Liverpool reign
-
China blocks Meta's acquisition of AI firm Manus
-
US woman speaks of ordeal in France Al-Fayed trafficking probe
-
French teen faces jail in Singapore for licking vending machine straw
-
Iran FM blames US for failure of talks after landing in Russia
-
Steep mountainside offers respite for daring Afghans
-
Teenage wonder Sooryavanshi says criticism 'affects me a bit'
-
Japan startup seeks approval of cat kidney disease treatment
-
Technician dies installing stage for Shakira concert in Rio
-
Cut off from the West, Muscovites rediscover Russian 'roots'
-
'Joint venture in reverse': foreign carmakers seek edge with China partners
-
Nations backing fossil fuel exit 'a new power': conference host Colombia
-
Rockets thrash Lakers, Wembanyama triumphant on Spurs return
-
ECB set to hold rates steady with eye on Iran crisis
-
Team-first Kane propelling Bayern to glory as PSG showdown looms
-
Pogacar vows to keep going until Seixas 'destroys' him
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
